Fresenius Medical Care is expanding its presence in China with acquisitions and investments in dialysis centres and renal hospitals. The company acquired a 70% share of Guangzhou KangNiDaiSi Medical Investment Co., Ltd, which focuses on dialysis and related chronic disease services, a 55% share of Henan Aishen Hospital Management Co. Ltd and Aishen Beijing Hospital Management, who are building 13 dialysis centres and a grade I renal hospital, and a 60% share of Daqing Kangda Dialysis Center Co., Ltd in Heilongjiang province.

“Fresenius invests in dialysis centres and renal hospitals in China.“

These acquisitions have been announced at the same time as the announcement of a weak profits outlook for 2019, and the likelihood that 2020 profit targets will not be reached. Shares dropped 17.71% on this news.